Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3593]

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

Pembrolizumab improves OS as first-line therapy in advanced NSCLC expressing <1% PD-L1 on tumours

Pembrolizumab improves OS as first-line therapy in advanced NSCLC expressing

Turning up the heat on resistant tumours with novel immunotherapies

Turning up the heat on resistant tumours with novel immunotherapies

Combined immunotherapy for lung cancer shows promise of success

Combined immunotherapy for lung cancer shows promise of success

Ramucirumab improves survival in second-line HCC

Ramucirumab improves survival in second-line HCC

European Commission approves expanded indication for denosumab for prevention of skeletal-related events in MM patients

European Commission approves expanded indication for denosumab for prevention of skeletal-related events in MM...

Impact of CMV on allogeneic HCT outcomes and cost-effectiveness of prophylactic therapy with letermovir

Impact of CMV on allogeneic HCT outcomes and cost-effectiveness of prophylactic therapy with letermovir

New receptor genes turn T-cells into powerful liver cancer foes

New receptor genes turn T-cells into powerful liver cancer foes

Genetic material once considered junk actually could hold key to cancer drug response

Genetic material once considered junk actually could hold key to cancer drug response

FDA grants accelerated approval to blinatumomab for B-cell precursor ALL

FDA grants accelerated approval to blinatumomab for B-cell precursor ALL

More from ecancer